Legend Biotech (LEGN) Price & Analysis

Compare

516 Followers

LEGN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$27.34 - $52.31

Previous CloseN/A

Volume249.07K

Average Volume (3M)1.09M

Market Cap

$6.11B

Enterprise Value$5.96B

Total Cash (Recent Filing)$967.64M

Total Debt (Recent Filing)$387.92M

Price to Earnings (P/E)―

Beta0.62

Next Earnings

Nov 24, 2025

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding184,570,710

10 Day Avg. Volume1,258,928

30 Day Avg. Volume1,089,207

Financial Highlights & Ratios

PEG Ratio0.25

Price to Book (P/B)2.86

Price to Sales (P/S)4.74

P/FCF Ratio-18.81

Enterprise Value/Market Cap0.97

Enterprise Value/Revenue7.47

Enterprise Value/Gross Profit12.08

Enterprise Value/Ebitda-22.87

Forecast

1Y Price Target

$76.27

Price Target Upside125.12% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

Bulls Say, Bears Say

Bulls Say

Market ExpansionCarvykti's expected sales of approximately $2B+ in 2025 could alleviate investor concerns regarding safety, manufacturing capacity, and the total addressable market.

Regulatory ChangesThe recent removal of REMS requirement for CAR-T infusion could boost Carvykti's accessibility and ease of use.

Sales GrowthCarvykti's average weekly US sales during late June to early August are approximately 9% higher than the previous quarter, indicating strong growth momentum.

Bears Say

Investor ConcernsCash and equivalents of $1 billion at the end of the second quarter provide a financial runway to profitability in 2026, potentially reducing investor concerns.

Manufacturing CapacityManagement has reiterated guidance of manufacturing 10,000 doses by year-end with an expansion to its Raritan facility and initiation of commercial production at Tech Lane Belgium Facility coming online in 2H25.

Market Penetration ChallengesTexas removed Foundation for the Accreditation of Cellular Therapy accreditation as a reimbursement requirement—these changes are slated to accelerate broader adoption.

Legend Biotech News

Legend Biotech in talks for listing outside U.S., Bloomberg says

Legend Biotech (LEGN) has discussed a second listing outside the U.S. with potential advisers, Julia Fioretti, Manuel Baigorri...

12d ago

LEGN

Legend Biotech assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of Legend Biotech (LEGN) with an Overweight rating and price target of $66, up...

21d ago

LEGN

Legend Biotech price target raised to $78 from $77 at JPMorgan

JPMorgan analyst Jessica Fye raised the firm’s price target on Legend Biotech (LEGN) to $78 from $77 and...

24d ago

LEGN

Legend Biotech Appoints Carlos Santos as CFO to Drive Financial Strategy

Legend Biotech ( ($LEGN) ) just unveiled an announcement. Legend Biotech announced the appointment of Carlos Santos as...

1M ago

LEGN

Legend Biotech appoints Santos as Chief Financial Officer

Legend Biotech (LEGN) announces the appointment of Carlos Santos as the Company’s Chief Financial Officer, effective immediately. Santos...

1M ago

LEGN

Legend Biotech’s Earnings Call: Growth and Success

Legend Biotech Corporation (($LEGN)) has held its Q2 earnings call. Read on for the main highlights of the...

1M ago

LEGN

Legend Biotech price target raised to $77 from $75 at RBC Capital

RBC Capital raised the firm’s price target on Legend Biotech (LEGN) to $77 from $75 and keeps an...

1M ago

LEGN

Positive Outlook for Legend Biotech: Strong Sales Growth and Strategic Advancements Drive Buy Rating

Kostas Biliouris, an analyst from BMO Capital, maintained the Buy rating on Legend Biotech. The associated price target...

1M ago

LEGN

Legend Biotech’s Strategic Growth and Record Sales Drive Buy Rating

Legend Biotech, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Justin Zelin from...

1M ago

LEGN

Strong Buy Rating for Legend Biotech Driven by CARVYKTI’s Market Success and Strategic Expansions

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Legend Biotech. The associated price target...

1M ago

LEGN

Legend Biotech’s Q2 2025: Strong CARVYKTI Sales and Strategic Growth

Legend Biotech Corporation ( ($LEGN) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

LEGN

UnitedHealth Stock (UNH) Tumbles 50% YTD; Here’s How to Buy the Dip Without the Risk

UnitedHealth Group ($UNH), the largest U.S. health insurer, recently suffered one of its worst stock plunges, down over...

1M ago

ABT

DHR

Legend Biotech’s Hold Rating: Balancing Strong Revenue Growth with Strategic Uncertainties

William Blair analyst Sami Corwin has maintained their neutral stance on LEGN stock, giving a Hold rating on...

1M ago

LEGN

Legend Biotech Reports Strong Q2 2025 Results and CARVYKTI® Success

An update from Legend Biotech ( ($LEGN) ) is now available. Legend Biotech reported its second quarter 2025...

1M ago

LEGN

LEGN FAQ

What was Legend Biotech Corporation’s price range in the past 12 months?

Legend Biotech Corporation lowest stock price was $27.34 and its highest was $52.31 in the past 12 months.

What is Legend Biotech Corporation’s market cap?

Legend Biotech Corporation’s market cap is $6.11B.

When is Legend Biotech Corporation’s upcoming earnings report date?

Legend Biotech Corporation’s upcoming earnings report date is Nov 24, 2025 which is in 68 days.

How were Legend Biotech Corporation’s earnings last quarter?

Legend Biotech Corporation released its earnings results on Aug 11, 2025. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.113 by -$0.227.

Is Legend Biotech Corporation overvalued?

According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Legend Biotech Corporation pay dividends?

Legend Biotech Corporation does not currently pay dividends.

What is Legend Biotech Corporation’s EPS estimate?

Legend Biotech Corporation’s EPS estimate is -0.04.

How many shares outstanding does Legend Biotech Corporation have?

Legend Biotech Corporation has 184,570,710 shares outstanding.

What happened to Legend Biotech Corporation’s price movement after its last earnings report?

Legend Biotech Corporation reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.113. Following the earnings report the stock price went down -2.054%.

Which hedge fund is a major shareholder of Legend Biotech Corporation?

Currently, no hedge funds are holding shares in LEGN

Legend Biotech Stock Smart Score

Outperform

Fundamentals

Return on Equity

-29.70%

Trailing 12-Months

Asset Growth

-6.02%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Legend Biotech Corporation

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Legend Biotech (LEGN) Earnings & Revenues

Historic Earnings Reports

LEGN Company Deck

LEGN Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a predominantly positive sentiment with significant achievements in sales growth, regulatory advancements, and clinical trial results. The company's strategic expansion in global markets and operational improvements further bolster this positive outlook. However, challenges such as ongoing net losses and early-stage community oncology expansion temper the overall sentiment.View all LEGN earnings summaries

LEGN Stock 12 Month Forecast

Average Price Target

$76.27

▲(125.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"$28","95":"$95","44.75":"$44.8","61.5":"$61.5","78.25":"$78.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$94.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":76.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$76.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$54.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,44.75,61.5,78.25,95],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.22,38.818461538461534,43.41692307692308,48.01538461538462,52.613846153846154,57.21230769230769,61.81076923076923,66.40923076923077,71.00769230769231,75.60615384615384,80.20461538461538,84.80307692307693,89.40153846153846,{"y":94,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.22,37.45461538461538,40.68923076923077,43.92384615384615,47.15846153846154,50.39307692307692,53.6276923076923,56.86230769230769,60.096923076923076,63.33153846153846,66.56615384615384,69.80076923076922,73.0353846153846,{"y":76.27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.22,35.74153846153846,37.26307692307692,38.784615384615385,40.30615384615385,41.82769230769231,43.34923076923077,44.87076923076923,46.392307692307696,47.91384615384615,49.43538461538462,50.956923076923076,52.47846153846154,{"y":54,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":57.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.48,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.36,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.31,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.1,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.52,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.32,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.29,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.22,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >